High Levels of Psychological Resilience Are Associated With Decreased Anxiety in Inflammatory Bowel Disease.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
03 06 2022
Historique:
received: 14 04 2021
pubmed: 28 8 2021
medline: 9 6 2022
entrez: 27 8 2021
Statut: ppublish

Résumé

Anxiety and depression are comorbid disorders with IBD and are associated with poor outcomes. Resilience is an innate but modifiable trait that may improve the symptoms of psychological disorders. Increasing resilience may decrease the severity of these comorbid disorders, which may improve IBD outcomes. The aim of this study was to describe the association between resilience, anxiety, and depression in IBD patients. We performed a cross-sectional study of IBD patients. Patients completed a questionnaire consisting of the Connor-Davidson Resilience Scale (CD-RISC), a measure of resilience, the Generalized Anxiety Disorder 7 (GAD-7), and the Patient Health Questionnaire-9. Primary outcome was severity of anxiety and depression in patients with high resilience. Multivariable linear regression analysis evaluated the association between severity of anxiety and depression and level of resilience. A sample of 288 patients was analyzed. Bivariable linear regression analysis showed a negative association between resilience and anxiety (Pearson rho = -0.47; P < .0001) and between resilience and depression (Pearson rho = -0.53; P < .0001). Multivariable linear regression indicated that high resilience is independently associated with lower anxiety and that for every 1-unit increase in CD-RISC, the GAD-7 score decreased by 0.04 units (P = .0003). Unlike anxiety, the association between resilience and depression did not remain statistically significant on multivariable analysis. High resilience is independently associated with lower anxiety in IBD patients, and we report a quantifiable decrease in anxiety score severity for every point of increase in resilience score. These findings suggest that IBD patients with higher resilience may have better coping mechanisms that buffer against the development of anxiety.

Sections du résumé

BACKGROUND
Anxiety and depression are comorbid disorders with IBD and are associated with poor outcomes. Resilience is an innate but modifiable trait that may improve the symptoms of psychological disorders. Increasing resilience may decrease the severity of these comorbid disorders, which may improve IBD outcomes. The aim of this study was to describe the association between resilience, anxiety, and depression in IBD patients.
METHODS
We performed a cross-sectional study of IBD patients. Patients completed a questionnaire consisting of the Connor-Davidson Resilience Scale (CD-RISC), a measure of resilience, the Generalized Anxiety Disorder 7 (GAD-7), and the Patient Health Questionnaire-9. Primary outcome was severity of anxiety and depression in patients with high resilience. Multivariable linear regression analysis evaluated the association between severity of anxiety and depression and level of resilience.
RESULTS
A sample of 288 patients was analyzed. Bivariable linear regression analysis showed a negative association between resilience and anxiety (Pearson rho = -0.47; P < .0001) and between resilience and depression (Pearson rho = -0.53; P < .0001). Multivariable linear regression indicated that high resilience is independently associated with lower anxiety and that for every 1-unit increase in CD-RISC, the GAD-7 score decreased by 0.04 units (P = .0003). Unlike anxiety, the association between resilience and depression did not remain statistically significant on multivariable analysis.
CONCLUSIONS
High resilience is independently associated with lower anxiety in IBD patients, and we report a quantifiable decrease in anxiety score severity for every point of increase in resilience score. These findings suggest that IBD patients with higher resilience may have better coping mechanisms that buffer against the development of anxiety.

Identifiants

pubmed: 34448855
pii: 6358608
doi: 10.1093/ibd/izab200
pmc: PMC9165553
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

888-894

Subventions

Organisme : NIDDK NIH HHS
ID : K23 DK111995
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation 2021.

Références

Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Dtsch Arztebl Int. 2018 Sep 21;115(38):621-627
pubmed: 30373706
Neuropsychiatr Dis Treat. 2016 Mar 24;12:673-83
pubmed: 27069364
Inflamm Bowel Dis. 2019 Aug 20;25(9):1577-1585
pubmed: 30840762
Inflamm Bowel Dis. 2017 Mar;23(3):341-346
pubmed: 28178002
Clin Psychol Rev. 2018 Feb;59:78-100
pubmed: 29167029
Int Wound J. 2019 Mar;16 Suppl 1:62-70
pubmed: 30793856
J Affect Disord. 2016 Oct;203:213-220
pubmed: 27310100
BMJ Open. 2018 Jun 14;8(6):e017858
pubmed: 29903782
Aliment Pharmacol Ther. 2013 Oct;38(7):761-71
pubmed: 23957526
Inflamm Bowel Dis. 2016 Mar;22(3):752-62
pubmed: 26841224
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7
pubmed: 26323879
Psychoneuroendocrinology. 2020 Jan;111:104501
pubmed: 31715444
Inflamm Bowel Dis. 2010 Oct;16(10):1685-95
pubmed: 20155849
Gastroenterol Hepatol (N Y). 2017 Mar;13(3):164-169
pubmed: 28539843
J Affect Disord. 2019 Feb 15;245:419-427
pubmed: 30423470
Psychosom Med. 2004 Jan-Feb;66(1):79-84
pubmed: 14747641
Inflamm Bowel Dis. 2021 May 17;27(6):791-796
pubmed: 32696966
Curr Neuropharmacol. 2010 Dec;8(4):335-58
pubmed: 21629442
J Gastroenterol Hepatol. 2010 Jul;25(7):1250-8
pubmed: 20594252
Neurogastroenterol Motil. 2018 Jan;30(1):
pubmed: 28718999
Eur J Psychotraumatol. 2014 Oct 01;5:
pubmed: 25317258
Inflamm Bowel Dis. 2018 Oct 12;24(11):2303-2308
pubmed: 29788469
Am J Gastroenterol. 2008 Aug;103(8):1989-97
pubmed: 18796096
Behav Res Ther. 2011 Mar;49(3):145-50
pubmed: 21256475
Depress Anxiety. 2003;18(2):76-82
pubmed: 12964174
CNS Spectr. 2016 Apr;21(2):184-98
pubmed: 26307347
Clin Transl Gastroenterol. 2017 Jan 19;8(1):e214
pubmed: 28102860
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971
J Psychiatr Res. 2009 Aug;43(12):1007-12
pubmed: 19264325
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941

Auteurs

Alicia Philippou (A)

Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Priya Sehgal (P)

Division of Digestive and Liver Disease, Columbia University Irving Medical Center, New York, New York, USA.

Ryan C Ungaro (RC)

The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Kelly Wang (K)

The Center for Biostatistics at the Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Emilia Bagiella (E)

The Center for Biostatistics at the Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Marla C Dubinsky (MC)

The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Laurie Keefer (L)

The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH